BACKGROUND: Painful events are the leading cause of hospitalizations for patients with sickle cell disease. Individualized pain plans targeting patient-specific maximum opioid dosing may shorten hospitalization length and are recommended by national guidelines. Prior to implementing individualized sickle cell pain plans, we tested the hypothesis that a shorter time to achieve a maximum opioid dose would improve hospitalization outcomes. PROCEDURE: Two-year IRB-approved, retrospective study of pediatric patients admitted for vaso-occlusive crisis (VOC). We recorded the emergency department admission time, order entry time for the maximum opioid dose during the hospitalization, and time of discharge orders. We categorized patients as infrequent if they required <3 admissions for VOC over two years and patients as frequent if they required ≥3 admissions for VOC over two years. To account for multiple admissions, generalized linear modeling was performed. RESULTS: We identified 236 admissions for acute pain observed in 108 patients. Achieving an earlier maximum opioid dose was significantly associated with shorter length of hospitalization for frequent and infrequent pain patients (both P ≤ 0.0001). As total hospitalization length can be impacted by the time a maximum opioid order was placed, we also analyzed hospitalization length after the maximum opioid order was placed. Frequent pain patients who achieved earlier analgesia had a significantly shorter hospitalization from the time the maximum opioid order was placed (P = 0.03) while no association was found for infrequent pain patients (P = 0.84). CONCLUSIONS: Early achievement of maximum analgesia improved hospitalization outcomes and warrant further investigation in prospective studies of individualized pain plans.
BACKGROUND: Painful events are the leading cause of hospitalizations for patients with sickle cell disease. Individualized pain plans targeting patient-specific maximum opioid dosing may shorten hospitalization length and are recommended by national guidelines. Prior to implementing individualized sickle cell pain plans, we tested the hypothesis that a shorter time to achieve a maximum opioid dose would improve hospitalization outcomes. PROCEDURE: Two-year IRB-approved, retrospective study of pediatric patients admitted for vaso-occlusive crisis (VOC). We recorded the emergency department admission time, order entry time for the maximum opioid dose during the hospitalization, and time of discharge orders. We categorized patients as infrequent if they required <3 admissions for VOC over two years and patients as frequent if they required ≥3 admissions for VOC over two years. To account for multiple admissions, generalized linear modeling was performed. RESULTS: We identified 236 admissions for acute pain observed in 108 patients. Achieving an earlier maximum opioid dose was significantly associated with shorter length of hospitalization for frequent and infrequent painpatients (both P ≤ 0.0001). As total hospitalization length can be impacted by the time a maximum opioid order was placed, we also analyzed hospitalization length after the maximum opioid order was placed. Frequent painpatients who achieved earlier analgesia had a significantly shorter hospitalization from the time the maximum opioid order was placed (P = 0.03) while no association was found for infrequent painpatients (P = 0.84). CONCLUSIONS: Early achievement of maximum analgesia improved hospitalization outcomes and warrant further investigation in prospective studies of individualized pain plans.
Authors: Matthew P Lazio; Heather H Costello; D Mark Courtney; Zoran Martinovich; Randall Myers; Amy Zosel; Paula Tanabe Journal: Clin J Pain Date: 2010 Mar-Apr Impact factor: 3.442
Authors: Robert E Molokie; Chariz Montminy; Corissa Dionisio; Muhammad Ahmen Farooqui; Michel Gowhari; Yingwei Yao; Marie L Suarez; Miriam O Ezenwa; Judith M Schlaeger; Zaijie J Wang; Diana J Wilkie Journal: Am J Emerg Med Date: 2017-07-13 Impact factor: 2.469
Authors: Paula Tanabe; Susan Silva; Hayden B Bosworth; Regina Crawford; Judith A Paice; Lynne D Richardson; Christopher N Miller; Jeffrey Glassberg Journal: Am J Hematol Date: 2017-11-10 Impact factor: 10.047
Authors: Paula Tanabe; Randall Myers; Amy Zosel; Jane Brice; Altaf H Ansari; Julia Evans; Zoran Martinovich; Knox H Todd; Judith A Paice Journal: Acad Emerg Med Date: 2007-03-26 Impact factor: 3.451
Authors: Deepika S Darbari; Onyinye Onyekwere; Mehdi Nouraie; Caterina P Minniti; Lori Luchtman-Jones; Sohail Rana; Craig Sable; Gregory Ensing; Niti Dham; Andrew Campbell; Manuel Arteta; Mark T Gladwin; Oswaldo Castro; James G Taylor; Gregory J Kato; Victor Gordeuk Journal: J Pediatr Date: 2011-09-03 Impact factor: 4.406
Authors: S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds Journal: N Engl J Med Date: 1995-05-18 Impact factor: 91.245
Authors: William T Zempsky; Kristin A Loiselle; Kathleen McKay; Brian H Lee; J Nathan Hagstrom; Neil L Schechter Journal: J Emerg Med Date: 2009-08-22 Impact factor: 1.484
Authors: Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah Journal: JAMA Date: 2014-09-10 Impact factor: 56.272
Authors: Amanda M Brandow; Mark Nimmer; Timothy Simmons; T Charles Casper; Lawrence J Cook; Corrie E Chumpitazi; J Paul Scott; Julie A Panepinto; David C Brousseau Journal: Am J Hematol Date: 2016-09-03 Impact factor: 10.047
Authors: Yves Duroseau; David Beenhouwer; Michael S Broder; Bonnie Brown; Tartania Brown; Sarah N Gibbs; Kaedrea Jackson; Sally Liang; Melanie Malloy; Marie-Laure Romney; Dana Shani; Jena Simon; Irina Yermilov Journal: J Am Coll Emerg Physicians Open Date: 2021-08-07